强生-话题@MedSci

#强生#

169篇内容 | 4607人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1271605, encodeId=f6cb12e1605e9, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生丙肝新药Sovriad（simeprevir）获日本批准, objectType=article, longId=25214, objectId=265b25214b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=265b25214b8, replyNumber=0, likeNumber=68, createdTime=2013-10-10, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=265b25214b8, moduleTitle=强生丙肝新药Sovriad（simeprevir）获日本批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=265b25214b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271604, encodeId=bba112e16044b, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生万珂（Velcade）VD和VTD诱导疗法方案获EC批准, objectType=article, longId=22883, objectId=e85422883b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e85422883b5, replyNumber=0, likeNumber=67, createdTime=2013-08-14, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e85422883b5, moduleTitle=强生万珂（Velcade）VD和VTD诱导疗法方案获EC批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e85422883b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271603, encodeId=268612e16039c, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=FDA：强生Simponi Aria获FDA批准用于RA, objectType=article, longId=21946, objectId=cd392194632, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd392194632, replyNumber=0, likeNumber=90, createdTime=2013-07-26, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd392194632, moduleTitle=FDA：强生Simponi Aria获FDA批准用于RA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd392194632)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271602, encodeId=0d2612e160204, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=FDA批准强生旗下戈利木单抗治疗溃疡性结肠炎新适应症, objectType=article, longId=19025, objectId=36c7190258f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36c7190258f, replyNumber=0, likeNumber=104, createdTime=2013-05-22, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36c7190258f, moduleTitle=FDA批准强生旗下戈利木单抗治疗溃疡性结肠炎新适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36c7190258f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271601, encodeId=058812e1601c5, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=辉瑞及强生bapineuzumab阿尔茨海默氏症项目III期试验失败, objectType=article, longId=8429, objectId=4e8c842994, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e8c842994, replyNumber=0, likeNumber=63, createdTime=2012-08-03, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e8c842994, moduleTitle=辉瑞及强生bapineuzumab阿尔茨海默氏症项目III期试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e8c842994)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271600, encodeId=584612e1600ac, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生召回部分问题球囊扩张导管, objectType=article, longId=7909, objectId=2f94e90966, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f94e90966, replyNumber=0, likeNumber=98, createdTime=2012-07-19, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f94e90966, moduleTitle=强生召回部分问题球囊扩张导管, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f94e90966)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271599, encodeId=1e9f12e15990e, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生拜耳的拜瑞妥（Xarelto）新适应证申请遭FDA评审委员会拒绝, objectType=article, longId=6484, objectId=92836484f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92836484f5, replyNumber=0, likeNumber=72, createdTime=2012-05-26, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92836484f5, moduleTitle=强生拜耳的拜瑞妥（Xarelto）新适应证申请遭FDA评审委员会拒绝, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92836484f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271598, encodeId=01d412e1598d5, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生在美召回儿童退烧药泰诺, objectType=article, longId=4136, objectId=6ef84136b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ef84136b2, replyNumber=0, likeNumber=74, createdTime=2012-02-26, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ef84136b2, moduleTitle=强生在美召回儿童退烧药泰诺, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ef84136b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271597, encodeId=85c512e159705, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=全球医疗器械十强收入盘点，强生独孤求败, objectType=article, longId=3531, objectId=e1b73531c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1b73531c8, replyNumber=0, likeNumber=77, createdTime=2011-12-19, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1b73531c8, moduleTitle=全球医疗器械十强收入盘点，强生独孤求败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1b73531c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

强生

2020-05-29

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生丙肝新药Sovriad（simeprevir）获日本批准

2013-10-10

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生万珂（Velcade）VD和VTD诱导疗法方案获EC批准

2013-08-14

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

FDA：强生Simponi Aria获FDA批准用于RA

2013-07-26

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

FDA批准强生旗下戈利木单抗治疗溃疡性结肠炎新适应症

2013-05-22

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

辉瑞及强生bapineuzumab阿尔茨海默氏症项目III期试验失败

2012-08-03

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生召回部分问题球囊扩张导管

2012-07-19

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生拜耳的拜瑞妥（Xarelto）新适应证申请遭FDA评审委员会拒绝

2012-05-26

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生在美召回儿童退烧药泰诺

2012-02-26

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

全球医疗器械十强收入盘点，强生独孤求败

2011-12-19

科室
- - 订阅+
  - 更多科室
工具
服务